Validation of analytic methods for biomarkers used in drug development.
The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.
Chau
Cindy H
CH
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Rixe
Olivier
O
McLeod
Howard
H
Figg
William D
WD
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015415:Biomarkers; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D015894:Genome, Human; D023281:Genomics; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015415:Biomarkers; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor